Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 44OTHER 22NIH 4NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Hodgkin Disease 7Lymphoma 6Melanoma 4Sarcoma 2Solitary Fibrous Tumors 1HIV Infections 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3Vinblastine 2Temozolomide 2Radiotherapy 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1lorukafusp alfa 1incomplete Freund's adjuvant 1dipeptidase 1 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × Melanoma × Dacarbazine × Clear all
NCT01152788 2023-08-22

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Canadian Cancer Trials Group

Phase 2 Completed
64 enrolled 10 charts
Dermatologic

Melanoma

NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Eastern Cooperative Oncology Group

Phase 3 Completed
482 enrolled
Dermatologic

Melanoma

NCT00006237 2015-03-25

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

SWOG Cancer Research Network

Phase 3 Completed
432 enrolled 7 charts
Dermatologic

Melanoma

NCT00002669 2012-07-02

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
90 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡